Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07166302

Acronym

U-HAND

Enrollment

Registered

2025-09-10

Start date

2025-09-30

Completion date

2026-12-31

Last updated

2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Direct Acting Anticoagulant Adverse Reaction, EMG, Mononeuropathies, Needle Injury, Neuromuscular Diseases (NMD), Peripheral Neuropathies, Polyneuropathies

Keywords

electromyography, hematoma, ultrasonography, anticoagulants

Brief summary

Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hematomas at the muscles where the EMG needle was inserted. These hematomas are considered a potential adverse effect of needle EMG. The aim of the study is to determine whether needle EMG can be considered a safe procedure in this group of patients, without posing a risk of intramuscular hematoma formation.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Subjects must understand the nature of the study and must provide signed and dated written informed consent prior to conducting any study-related procedures * Willing and able to comply with all protocol procedures * subjects confirmed the daily (and recent) intake od direct anticoagulants in strandard dosing. * no other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is taken.

Exclusion criteria

* Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject * other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is recently taken.

Design outcomes

Primary

Measure	Time frame	Description
Intramuscular hematoma risk	seven days since the needle EMG	Ultrasound evaluation of intramuscular hematoma formation after needle EMG in DOAC patients

Countries

Czechia

Contacts

Primary ContactAdam Betík, MD

betik.adam@fnbrno.cz+420532232503

Backup ContactEva Vlckova, MD

vlckova.eva@fnbrno.cz+420532233221

Outcome results